Proteonomix, Inc., has announced that Michael Cohen, Chief Executive Officer of Proteonomix and Ian McNiece, the Company's Chief Scientific Officer met with the team at Gilford Securities, the Company's Investment Banker, and Aegis Capital.
They updated them on the development of the Company's technology and the Company's technical position in several different areas of research and development.
Proteonomix CEO Michael Cohen stated, "Proteonomix is on the cusp of entering a new phase of its development and well on its way to becoming a significant force in the biotech world. We are at present not covered by any analysts in the industry and hope to gain such coverage in the near future. We anticipate that such coverage will assist the investing public is recognizing the achievements of Proteonomix both in bringing our Proteoderm anti-aging skin care line to the point where marketing can commence, as well as moving ever closer to commencement of clinical trials for our StromaCel cardiovascular disease therapy and our UMK-121 liver treatment."
Ian McNiece, the Proteonomix Chief Scientific Officer and a member of the Board, noted, "Our Company has made extraordinary progress on a limited budget both in the realm of product development and in its working relationship with the academic community. Our anticipated clinical trial moves ever closer to fruition and the Company's patent position is remarkable for such an early stage company."
The Company will be filing a version of the PowerPoint presentation made today, along with the Form 8-K filing for this press release.